---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-08-29T11:31:45.637747'
end_time: '2026-08-29T11:49:08.428817'
duration_seconds: 1042.79
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Autosomal Recessive Cutis Laxa Type 2A
  mondo_id: MONDO:0018163
  category: Genetic
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 15
reference_validation:
  total_references: 17
  verified: 17
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 17
  on_topic: 14
  validator_version: 0.2.1
term_validation:
  total_terms: 41
  verified: 39
  not_found: 0
  obsolete: 1
  unverifiable: 1
  confabulation_rate: 0.0
  labels_checked: 6
  labels_matching: 4
  labels_mismatched: 1
  mislabelled_terms:
  - term_id: MONDO:0018163
    reported_labels:
    - MONDO
    ontology_label: autosomal recessive cutis laxa type 2A
  labels_variant: 1
  obsolete_terms:
  - term_id: GO:0006486
    ontology_label: obsolete protein glycosylation
    replaced_by: GO:0009101
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Autosomal_Recessive_Cutis_Laxa_Type_2A-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Autosomal_Recessive_Cutis_Laxa_Type_2A-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Autosomal Recessive Cutis Laxa Type 2A
- **MONDO ID:** MONDO:0018163 (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on **Autosomal Recessive Cutis Laxa Type 2A** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Autosomal Recessive Cutis Laxa Type 2A (ARCL2A): Comprehensive Disease Characterization

**Disease:** Autosomal Recessive Cutis Laxa Type 2A
**MONDO ID:** MONDO:0018163 · **OMIM:** 219200 · **Gene:** *ATP6V0A2* (HGNC:865)
**Category:** Genetic (rare autosomal recessive connective-tissue disorder / congenital disorder of glycosylation type II)

---

## Summary

Autosomal Recessive Cutis Laxa Type 2A (ARCL2A) is a rare, autosomal recessive, multisystem connective-tissue disorder caused by **biallelic loss-of-function variants in *ATP6V0A2***, the gene encoding the **a2 subunit of the vacuolar (V-type) H⁺-ATPase (V-ATPase)** that resides in the trans-Golgi membrane. Because this proton pump normally acidifies the Golgi lumen, its loss elevates Golgi pH and produces a **combined defect of N-linked and mucin-type O-linked glycosylation**, placing ARCL2A within the congenital disorders of glycosylation type II (CDG-II) spectrum. The hallmark of the disease is generalized, redundant, sagging/wrinkled skin (cutis laxa), accompanied by a variable constellation of skeletal, neurological, dysmorphic, and ophthalmologic features. ARCL2A overlaps clinically and mechanistically with wrinkly skin syndrome (WSS), which is now recognized as a phenotypic variant of the same disorder.

Mechanistically, V0a2 deficiency causes a fragmented Golgi, delayed brefeldin-A-induced retrograde transport, intracellular retention of tropoelastin with a secretion block, reduced deposition of mature extracellular elastin, elevated TGF-β signaling, and increased apoptosis. In the developing brain, elevated Golgi pH correlates with aberrant cortical neuron migration, explaining the neurological features (developmental delay, intellectual disability, epilepsy, and gyration/migration abnormalities). The phenotype is age-dependent: earlier ascertainment is significantly associated with more severe systemic involvement, while an **attenuated adult phenotype dominated by cutaneous findings** exists and generally carries a favorable prognosis. The skin laxity tends to attenuate with age.

There is **no disease-specific or curative therapy**; management is symptomatic and multidisciplinary (dermatologic, developmental/neurologic, orthopedic, and ophthalmologic surveillance). Because cutis laxa syndromes are clinically heterogeneous and overlapping, **molecular confirmation is required for definitive diagnosis**, ideally preceded by biochemical screening with combined transferrin and apolipoprotein C-III isoelectric focusing to detect the characteristic combined N-/O-glycosylation defect. The disease occurs worldwide, is enriched in consanguineous populations, and displays founder effects (e.g., a recurrent exon 16 deletion in southeastern Türkiye). An *Atp6v0a2* knockout mouse recapitulates the core Golgi-pH, glycosylation, and neuronal-migration phenotypes and additionally displays globozoospermia.

---

## 1. Disease Information

**Overview.** ARCL2A is a rare inherited connective-tissue disorder characterized by loose, redundant, inelastic, wrinkled skin (cutis laxa) together with a variable spectrum of skeletal, neurodevelopmental, craniofacial, and ophthalmologic abnormalities. It is simultaneously classified as a **congenital disorder of glycosylation (CDG type II)** because the underlying V-ATPase defect impairs both N-linked and O-linked glycan biosynthesis in the Golgi.

**Key identifiers.**

| Resource | Identifier |
|---|---|
| OMIM | 219200 |
| MONDO | MONDO:0018163 |
| Gene | *ATP6V0A2* (HGNC:865; chr 12q24.31) |
| Disease family | Autosomal recessive cutis laxa type 2 (CDG-II subgroup) |

**Synonyms / alternative names.** ARCL2A; ATP6V0A2-related cutis laxa; ATP6V0A2-CDG; cutis laxa type IIA; wrinkly skin syndrome (WSS, considered a phenotypic variant of the same disorder). The clinical continuum between severe cutis laxa and milder wrinkly skin syndrome reflects allelic variation at the same locus ([PMID: 19401719](https://pubmed.ncbi.nlm.nih.gov/19401719/)).

**Source of information.** The characterization here is derived from **aggregated disease-level resources** — OMIM, systematic reviews, cohort studies, and case reports in the primary literature — rather than individual patient EHR data.

---

## 2. Etiology

**Primary cause — genetic.** ARCL2A is caused by **biallelic (homozygous or compound heterozygous) loss-of-function variants in *ATP6V0A2***, which encodes the a2 subunit of the V-type H⁺-ATPase (Finding F001). Kornak et al. first identified these loss-of-function mutations in multiple families with autosomal recessive cutis laxa type II / wrinkly skin syndrome:

> *"We identified loss-of-function mutations in ATP6V0A2, encoding the a2 subunit of the V-type H+ ATPase, in several families with autosomal recessive cutis laxa type II or wrinkly skin syndrome."* — [PMID: 18157129](https://pubmed.ncbi.nlm.nih.gov/18157129/)

**Genetic risk factors.** The disease is monogenic and fully genetically determined by *ATP6V0A2* genotype; there are no known susceptibility loci beyond the causal gene. The dominant variant class is **predicted null alleles**. In the Morlino 2021 systematic review, **~78.3% of known variants were predicted null (nonsense, frameshift, splice)**, with 11 missense and 2 noncanonical splice variants (Finding F001):

> *"About 78.3% of known variants were predicted null alleles, while 11 were missense and 2 affected noncanonical splice sites."* — [PMID: 33369135](https://pubmed.ncbi.nlm.nih.gov/33369135/)

**Environmental risk factors.** None are established. ARCL2A is a Mendelian disorder; **parental consanguinity** is the principal epidemiological risk context because it increases the likelihood of homozygosity for rare recessive alleles (Finding F006). There are no known toxic, occupational, infectious, or lifestyle triggers.

**Protective factors.** No genetic or environmental protective factors have been defined. However, the **missense variant p.P87L is associated with unusually mild disease**, indicating that residual protein function attenuates severity (Finding F003).

**Gene–environment interactions.** None documented. The disease is essentially environment-independent; phenotypic variability appears driven by genotype (null vs. residual-function alleles) and developmental timing rather than gene–environment interaction.

---

## 3. Phenotypes

ARCL2A spans a continuum from a severe phenotype with skin, skeletal, and neurological involvement to an attenuated adult phenotype dominated by cutaneous features (Findings F004, F008). A central discriminator is **age at ascertainment**: earlier presentation correlates with more severe systemic involvement.

> *"Age at ascertainment appeared as the unique phenotypic discriminator with earlier age more commonly associated with facial dysmorphism (p .02), high/cleft palate (p .005), intellectual disability/global developmental delay (p .013), and seizures (p .024)."* — [PMID: 33369135](https://pubmed.ncbi.nlm.nih.gov/33369135/)

| Phenotype | Type | Onset | Severity / course | HPO suggestion |
|---|---|---|---|---|
| Cutis laxa (redundant, wrinkled, inelastic skin) | Physical manifestation | Congenital / neonatal | Generalized; tends to **attenuate with age** | HP:0000973 (Cutis laxa) |
| Facial dysmorphism (long philtrum, downslanting palpebral fissures, large nasal root) | Physical manifestation | Congenital | More common at earlier age (p=.02) | HP:0001999 (Abnormal facial shape) |
| High-arched / cleft palate | Clinical sign | Congenital | Enriched at earlier age (p=.005) | HP:0000218 / HP:0000175 |
| Large / late-closing fontanelles | Clinical sign | Neonatal / infancy | Variable | HP:0000239 (Large fontanelles) |
| Intellectual disability / global developmental delay | Behavioral / neurodevelopmental | Childhood | Enriched at earlier age (p=.013) | HP:0001249 / HP:0001263 |
| Seizures / epilepsy | Clinical sign | Childhood | Enriched at earlier age (p=.024); **most common in ATP6V0A2 defects** | HP:0001250 (Seizures) |
| Cortical gyration / neuronal migration abnormalities | Clinical sign (imaging) | Congenital | Mostly (not always) associated with ATP6V0A2 | HP:0002269 (Abnormal cortical gyration) |
| Skeletal anomalies (joint laxity, hip dislocation, growth deficiency) | Physical manifestation | Congenital / childhood | Variable | HP:0001382 / HP:0002827 |
| Corneal abnormalities (keratoconus, high astigmatism, corneal thinning/flattening) | Clinical sign | Childhood–adult | ATP6V0A2-specific reduced visual acuity | HP:0000563 / HP:0000539 |
| Chorioretinal / macular scarring | Clinical sign | Variable | Reduced visual acuity (case: 20/2000) | HP:0000532 / HP:0007401 |
| Combined N-/O-glycosylation defect (serum) | Laboratory abnormality | Congenital | Constant biochemical marker | — |

**Neurological features** are a distinguishing element of ARCL2A within the cutis laxa family. Epilepsy is the most common neurological finding in ATP6V0A2 defects, and gyration/migration abnormalities and abnormal glycosylation are mostly associated with ATP6V0A2 mutations (Finding F004):

> *"Epilepsy was most common in ATP6V0A2 defects."* — [PMID: 23963297](https://pubmed.ncbi.nlm.nih.gov/23963297/)

**Ocular involvement** (Finding F005) is increasingly recognized. In a Ghent cohort of 13 genetically confirmed cutis laxa patients (4 with ATP6V0A2), reduced visual acuity was detected **solely** in the ATP6V0A2 subtype:

> *"Reduced corrected visual acuity was detected solely in patients with the ATP6V0A2 subtype. Three (23.1%) cases of keratoconus were detected in the cohort. All 4 patients with ATP6V0A2-related CL had prominent corneal tomographic abnormalities, with either high-grade astigmatism or pronounced corneal flattening and thinning."* — [PMID: 40043299](https://pubmed.ncbi.nlm.nih.gov/40043299/)

Retinal involvement is documented in a case with macular and chorioretinal scarring:

> *"Funduscopic examination showed a round macular scar lesion in the right eye macula and a chorioretinal scar superonasally in the left eye."* — [PMID: 36728588](https://pubmed.ncbi.nlm.nih.gov/36728588/)

**Quality of life.** Per-phenotype QOL data (EQ-5D/SF-36) are not available for this rare disease. Functionally, the greatest burdens derive from neurodevelopmental impairment (in severe/early-onset cases), reduced visual acuity (ATP6V0A2-specific ocular disease), and the cosmetic/psychosocial impact of skin laxity. The attenuated phenotype, dominated by non-life-threatening cutaneous features, is compatible with a relatively favorable functional outcome (Finding F008).

---

## 4. Genetic / Molecular Information

**Causal gene.** *ATP6V0A2* (chr 12q24.31), encoding the a2 subunit of the trans-Golgi V-type H⁺-ATPase (Finding F001).

**Pathogenic variant spectrum.**
- **Variant classes:** predominantly null alleles. ~78.3% predicted null (nonsense, frameshift, canonical splice), 11 missense, 2 noncanonical splice ([PMID: 33369135](https://pubmed.ncbi.nlm.nih.gov/33369135/)).
- **Representative variants:** recurrent 380-bp exon 16 deletion c.1936-147_2055+113del (founder allele, Türkiye); c.235del (p.Leu79Phefs\*13); c.1977_1980del (p.Val660LeufsTer23, Pakistani family); missense p.P87L (unusually mild disease); multiple novel intronic/splice variants across Iranian, Han-Chinese, and other families (Findings F003, F006).
- **Functional consequence:** **loss of function.** Premature-stop mutations reduce *ATP6V0A2* mRNA via nonsense-mediated decay; the mutant protein is lost in patient dermal fibroblasts (Finding F003):

> *"Premature stop codon mutations led to decreased ATP6V0A2 mRNA levels by destabilizing the mutant mRNA via the nonsense-mediated decay pathway."* — [PMID: 19321599](https://pubmed.ncbi.nlm.nih.gov/19321599/)

- **Origin:** germline (biallelic). No somatic contribution.
- **Allele frequency:** individually rare/private; most alleles are population-specific and often observed in consanguineous families.

**Modifier genes / epigenetics.** No formal modifier genes or epigenetic mechanisms have been established for ARCL2A. Phenotypic variability is largely attributable to allele type (null vs residual function) and developmental timing.

**Chromosomal abnormalities.** ARCL2A is not caused by large-scale aneuploidy or translocations, though **intragenic structural deletions** (e.g., the recurrent exon 16 deletion) are an important variant class (Finding F006).

---

## 5. Environmental Information

**Environmental factors, lifestyle factors, and infectious agents are not applicable.** ARCL2A is a monogenic recessive disorder with no established environmental, toxic, occupational, dietary, or infectious contributors. The only relevant non-molecular epidemiological factor is **consanguinity**, which increases the probability of biallelic inheritance rather than acting as a disease-causing exposure.

---

## 6. Mechanism / Pathophysiology

### Causal chain

```
Biallelic LOF in ATP6V0A2
        │  (NMD of null alleles → loss of V0a2 protein)
        ▼
Loss of trans-Golgi V-ATPase a2 subunit
        │
        ▼
Elevated Golgi luminal pH (loss of proton pumping)
        │
        ├─► Combined N-/O-glycosylation defect (CDG-II)  ──► serum transferrin + apoC-III abnormality
        │
        ├─► Golgi fragmentation + delayed BFA-induced retrograde transport
        │            │
        │            ▼
        │     Impaired tropoelastin secretion → intracellular TE retention/aggregation
        │            │
        │            ▼
        │     ↓ extracellular mature elastin deposition + ↑ apoptosis ──► CUTIS LAXA
        │
        ├─► Elevated TGF-β1 signaling ──► dysregulated ECM homeostasis
        │
        └─► Aberrant cortical neuron migration ──► NEURODEVELOPMENTAL / EPILEPSY phenotype
```

### Molecular and cellular detail

**Golgi V-ATPase dysfunction.** ATP6V0A2 localizes to the Golgi apparatus, where the V-ATPase acidifies the lumen. Loss of V0a2 elevates Golgi pH. Kopp et al. (2024) directly demonstrated in *Atp6v0a2* knockout mice that this pH elevation correlates with tissue-specific glycosylation changes and aberrant cortical neuron migration (Findings F002, F007):

> *"Loss-of-function variants in ATP6V0A2, encoding the trans Golgi V-ATPase subunit V0a2, cause wrinkly skin syndrome (WSS), a connective tissue disorder with glycosylation defects and aberrant cortical neuron migration."* — [PMID: 39680136](https://pubmed.ncbi.nlm.nih.gov/39680136/)

**Impaired trafficking and TGF-β signaling.** Patient and knockdown cells show delayed brefeldin-A-induced Golgi collapse/retrograde transport, a fragmented Golgi, and elevated TGF-β signaling (Finding F002):

> *"Investigation of brefeldin A-induced Golgi collapse in dermal fibroblasts as well as in HeLa cells deficient for ATP6V0A2 revealed a delay"* — [PMID: 22773132](https://pubmed.ncbi.nlm.nih.gov/22773132/)

> *"fibroblasts from patients with ATP6V0A2 mutations displayed elevated TGF-β signalling and increased TGF-β1 levels in the supernatant"* — [PMID: 22773132](https://pubmed.ncbi.nlm.nih.gov/22773132/)

**Tropoelastin secretion block (the direct cause of cutis laxa).** Hucthagowder et al. (2009) showed in a 17-patient cohort that ATP6V0A2 loss produces distended Golgi cisternae and abnormal lysosomes/multivesicular bodies, with tropoelastin accumulating in the Golgi and forming abnormal intracellular/extracellular aggregates (Finding F003):

> *"Immunostaining of ARCL2 cells showed the accumulation of tropoelastin (TE) in the Golgi and in large, abnormal intracellular and extracellular aggregates. Pulse-chase studies confirmed impaired secretion and increased intracellular retention of TE, and insoluble elastin assays showed significantly reduced extracellular deposition of mature elastin."* — [PMID: 19321599](https://pubmed.ncbi.nlm.nih.gov/19321599/)

Notably, fibrillin-1 microfibril assembly and lysyl oxidase activity were **normal**, localizing the defect specifically to tropoelastin trafficking rather than downstream elastin crosslinking. TUNEL assays showed **increased apoptosis**, contributing to tissue fragility.

### Ontology anchors
- **Biological processes (GO):** protein glycosylation (GO:0006486); Golgi lumen acidification / regulation of pH (GO:0007035); retrograde transport, Golgi to ER (GO:0006890); extracellular matrix organization (GO:0030198); TGF-β receptor signaling (GO:0007179); apoptotic process (GO:0006915); neuron migration (GO:0001764).
- **Cellular components (GO):** Golgi membrane (GO:0000139); trans-Golgi network (GO:0005802); proton-transporting V-type ATPase complex (GO:0033176).
- **Cell types (CL):** dermal fibroblast (CL:0002620); cortical neuron / migrating neuron.
- **Chemical entities (CHEBI):** proton (CHEBI:24636); ATP (CHEBI:30616); N-glycan / O-glycan; sialic acid (CHEBI:26667).

---

## 7. Anatomical Structures Affected

| Level | Structures affected | Ontology suggestion |
|---|---|---|
| **Primary organ** | Skin (dermis; elastic fiber network) | UBERON:0002097 (skin of body); UBERON:0002067 (dermis) |
| **Secondary / systems** | Central nervous system (cerebral cortex); skeletal system (joints, hips, palate); eye (cornea, retina/macula) | UBERON:0000955 (brain); UBERON:0001456 (face); UBERON:0000970 (eye); UBERON:0000964 (cornea); UBERON:0000966 (retina) |
| **Body systems** | Integumentary, nervous, musculoskeletal, ophthalmic | — |
| **Tissue** | Connective tissue (elastic fibers); nervous tissue (migrating cortical neurons) | — |
| **Cell** | Dermal fibroblasts (tropoelastin producers); cortical neurons | CL:0002620; migrating neuron |
| **Subcellular** | Golgi apparatus / trans-Golgi network; secretory vesicles; lysosomes/multivesicular bodies | GO:0005802; GO:0005764 |
| **Localization / laterality** | Generalized skin involvement; ocular findings can be bilateral (corneal) or focal/asymmetric (macular/chorioretinal scars) | — |

The primary lesion is at the **subcellular level (Golgi)**, propagating to a **connective-tissue phenotype (dermis)** and a **neuronal migration phenotype (cortex)**.

---

## 8. Temporal Development

**Onset.** Congenital / neonatal. Skin laxity and dysmorphism are typically present from birth; large fontanelles and developmental concerns emerge in infancy (Finding F004).

**Progression.** ARCL2A is generally **non-progressive to attenuating**. Systemic features (facial dysmorphism, high/cleft palate, intellectual disability, seizures) are enriched at earlier ages, and the phenotype shifts over time toward one **dominated by cutaneous involvement**, with skin laxity tending to attenuate (Findings F004, F008):

> *"This work confirmed the existence of an attenuated phenotype associated with ATP6V0A2 biallelic variants and offers an updated critique to the clinical and molecular variability of ARCL2A."* — [PMID: 33369135](https://pubmed.ncbi.nlm.nih.gov/33369135/)

> *"The associated clinical spectrum subsequently expanded to a less severe phenotype dominated by cutaneous involvement."* — [PMID: 33369135](https://pubmed.ncbi.nlm.nih.gov/33369135/)

**Course and duration.** Chronic, lifelong genetic disorder. Rare severe congenital forms of ARCL type 2 can involve life-threatening neonatal pulmonary emphysema, but this is not typical of ARCL2A (Finding F008). A subset with a novel c.235del showed severe neurological regression, indicating variability at the severe end (Finding F006).

**Critical period.** The prenatal/perinatal window of cortical neuronal migration is the key period of vulnerability for the neurological phenotype (Finding F007).

---

## 9. Inheritance and Population

**Inheritance pattern.** Autosomal recessive; biallelic loss of function (Findings F001, F006).

**Epidemiology.** ARCL2A is very rare; precise prevalence/incidence figures are not established in registries. It occurs **worldwide** and is **enriched in consanguineous populations** (Finding F006).

**Founder effects and geographic distribution.** A recurrent homozygous 380-bp exon 16 deletion with a shared haplotype was identified in southeastern Türkiye, indicating a founder effect (Finding F006):

> *"Nine individuals carried a recurrent homozygous 380 bp deletion spanning exon 16 (c.1936-147_2055+113del). ... Haplotype analysis revealed shared homozygous regions in three cases, suggesting a founder effect."* — [PMID: 41732832](https://pubmed.ncbi.nlm.nih.gov/41732832/)

ARCL2A has been reported in Turkish, Pakistani, Iranian, Han-Chinese, Italian, and other families, frequently with documented parental consanguinity.

> *"Autosomal recessive cutis laxa type 2A (ARCL2A; OMIM: 219200) is characterized by neurovegetative, developmental and progeroid elastic skin anomalies. It is caused by biallelic variation in ATPase, H..."* — [PMID: 37119015](https://pubmed.ncbi.nlm.nih.gov/37119015/)

**Penetrance / expressivity.** Penetrance of biallelic null genotypes is effectively complete; **expressivity is highly variable** and age-dependent. No specific genotype–phenotype correlation was identified in the systematic review, aside from the observation that residual-function missense alleles (e.g., p.P87L) can be milder (Findings F003, F004).

**Sex ratio / anticipation / mosaicism.** No sex bias is expected (autosomal). Genetic anticipation is not applicable (no repeat expansion). Germline mosaicism is not a recognized feature.

**Carrier frequency.** Not formally established; expected to be low outside founder populations.

---

## 10. Diagnostics

### Biochemical screening (first-line gateway)
ARCL2A is a **CDG-II with a combined N-/O-glycosylation defect**. The validated first-line biochemical screen is **combined plasma transferrin isoelectric focusing (TIEF) plus apolipoprotein C-III (apoC-III) isoelectric focusing** (Finding F010). Transferrin IEF distinguishes N-glycan assembly (type 1) from processing (type 2/CDG-II) defects; apoC-III IEF detects core-1 mucin-type O-glycan defects. Together they detect the combined defect characteristic of ATP6V0A2 deficiency:

> *"Plasma apoC-III IEF is complementary to transferrin isofocusing. In conjunction both tests identify biosynthesis defects in N-glycan and mucin-type core 1 O-glycan biosynthesis."* — [PMID: 17170056](https://pubmed.ncbi.nlm.nih.gov/17170056/)

> *"the CDG-IIx patients could be further subdivided into six biochemical subgroups"* — [PMID: 16037491](https://pubmed.ncbi.nlm.nih.gov/16037491/)

ATP6V0A2 deficiency produces a CDG-II transferrin pattern together with an abnormal (hyposialylated) apoC-III O-glycan profile.

### Genetic testing (definitive)
Molecular confirmation is required (Finding F011). Recommended approaches:
- **Single-gene sequencing of *ATP6V0A2*** (with deletion/duplication analysis to detect intragenic structural variants such as the exon 16 deletion).
- **Gene panels** for cutis laxa / connective-tissue disorders (should include *ATP6V0A2*, *ATP6V1A*, *ATP6V1E1*, *PYCR1*, *ALDH18A1*, *ELN*, *FBLN4/5*).
- **Whole-exome / whole-genome sequencing** for phenotypic overlap cases; WGS improves detection of deep intronic/splice and structural variants.
- Minigene assays help classify novel splice variants.

### Histopathology
Skin biopsy shows sparse/fragmented dermal elastic fibers (orcein staining). Ultrastructure and cell studies show distended Golgi cisternae, abnormal lysosomes/multivesicular bodies, and intracellular tropoelastin aggregates.

### Differential diagnosis
Because cutis laxa syndromes share overlapping features, molecular diagnosis is essential (Finding F011):

> *"Thus, molecular diagnosis is the only way to resolve these phenotypically similar conditions."* — [PMID: 26538727](https://pubmed.ncbi.nlm.nih.gov/26538727/)

Key differentials and their discriminators:

| Condition | Gene | Distinguishing feature |
|---|---|---|
| ARCL2B / geroderma osteodysplasticum | *PYCR1* | Corpus callosum dysgenesis, dystonic posturing; wrinkling limited to hands/feet |
| ARCL3 / de Barsy syndrome | *ALDH18A1* | Progeroid, cataract, severe; corpus callosum dysgenesis, dystonic posturing |
| ARCL2C | *ATP6V1E1* | V-ATPase subunit; overlapping |
| ARCL2D | *ATP6V1A* | Shared Golgi/glycosylation pathomechanism |
| Geroderma osteodysplasticum | *GORAB* | Severe osteoporosis; **not** allelic to WSS |

> *"Corpus callosum dysgenesis was associated with PYCR1 and ALDH18A1 mutations. Dystonic posturing was discriminatory for PYCR1 and ALDH18A1 defects."* — [PMID: 23963297](https://pubmed.ncbi.nlm.nih.gov/23963297/)

### Screening
Carrier and cascade screening in affected families is appropriate; in founder populations (e.g., southeastern Türkiye) targeted testing for the recurrent allele is efficient. Prenatal/preimplantation genetic diagnosis is feasible once the familial variants are known.

---

## 11. Outcome / Prognosis

**Overall prognosis is generally favorable**, especially in the attenuated phenotype dominated by non-life-threatening cutaneous features (Finding F008). Skin laxity and dysmorphism tend to attenuate with age.

- **Survival / mortality:** No systematic survival data; the attenuated form is compatible with normal or near-normal life expectancy. The severe congenital end of the broader ARCL type 2 spectrum can rarely involve life-threatening neonatal pulmonary emphysema.
- **Morbidity / function:** Determined by neurodevelopmental impairment in severe/early cases and by ATP6V0A2-specific ocular disease (reduced visual acuity, keratoconus, corneal thinning). Skeletal features (joint laxity, hip dislocation) contribute to orthopedic morbidity.
- **Prognostic factors:** Earlier age at ascertainment predicts more severe systemic (facial, palatal, neurodevelopmental, seizure) involvement; residual-function alleles (e.g., missense p.P87L) predict milder disease (Findings F003, F004).

> *"This work confirmed the existence of an attenuated phenotype associated with ATP6V0A2 biallelic variants..."* — [PMID: 33369135](https://pubmed.ncbi.nlm.nih.gov/33369135/)

---

## 12. Treatment

**There is no disease-specific or curative therapy** for the underlying V-ATPase/glycosylation defect (Finding F008). Management is **symptomatic, supportive, and multidisciplinary**:

- **Dermatologic:** cosmetic/reconstructive plastic surgery for redundant skin where indicated; sun protection and skin care.
- **Neurologic / developmental:** anti-seizure medication for epilepsy; early developmental intervention, physical/occupational/speech therapy for developmental delay and intellectual disability.
- **Orthopedic:** management of joint laxity, hip dislocation, and skeletal anomalies; physiotherapy.
- **Ophthalmologic:** surveillance and correction for high astigmatism/keratoconus (spectacles, rigid contact lenses, corneal cross-linking where appropriate); management of retinal/macular lesions.
- **Craniofacial:** cleft/high-palate repair and feeding support as needed.

**Pharmacogenomics, gene therapy, cell therapy, RNA-based therapy, targeted therapy, and immunotherapy** are not established for ARCL2A. The *Atp6v0a2* knockout mouse provides a platform for future mechanism-based intervention studies. NCIT clinical-intervention terms would map primarily to supportive/rehabilitative and reconstructive-surgical categories (e.g., NCIT:C15329 Rehabilitation Therapy; NCIT:C15329-adjacent supportive-care terms; NCIT:C15265 Reconstructive Surgery).

---

## 13. Prevention

Because ARCL2A is a Mendelian recessive disorder with no environmental cause, prevention is **genetic and reproductive**, not lifestyle-based:

- **Genetic counseling** for at-risk families, especially those with consanguinity (25% recurrence risk per pregnancy for two carrier parents).
- **Carrier and cascade screening** of relatives once the familial *ATP6V0A2* variants are identified; efficient in founder populations via targeted testing (Finding F006).
- **Prenatal diagnosis / preimplantation genetic testing** for known familial variants.
- **Tertiary prevention:** ophthalmologic, neurologic, orthopedic, and developmental surveillance to prevent complications and optimize function.

Primary prevention by vaccination, behavioral change, or environmental modification is **not applicable**.

---

## 14. Other Species / Natural Disease

- **Taxonomy / orthologs:** The mouse ortholog *Atp6v0a2* is well characterized (see §15). Orthologs of the V-ATPase a2 subunit are broadly conserved across vertebrates, reflecting the essential housekeeping role of Golgi acidification.
- **Natural disease in other species:** No well-documented naturally occurring ARCL2A-equivalent disease in companion animals or wildlife is described in the reviewed literature.
- **Comparative biology / conservation:** The Golgi V-ATPase → glycosylation → connective-tissue/neuronal-migration axis is evolutionarily conserved, supporting cross-species modeling of the mechanism (Finding F007).
- **Transmission / zoonosis:** Not applicable (non-infectious genetic disorder).

---

## 15. Model Organisms

**Primary model — *Atp6v0a2* knockout mouse (Kopp et al., 2024).** This mammalian genetic knockout recapitulates the core disease mechanism and several key phenotypes (Finding F007):

> *"Loss-of-function variants in ATP6V0A2, encoding the trans Golgi V-ATPase subunit V0a2, cause wrinkly skin syndrome (WSS), a connective tissue disorder with glycosylation defects and aberrant cortical neuron migration."* — [PMID: 39680136](https://pubmed.ncbi.nlm.nih.gov/39680136/)

| Feature | Human ARCL2A | Atp6v0a2 KO mouse |
|---|---|---|
| Elevated Golgi pH | Inferred (mechanism) | Demonstrated |
| Tissue-specific glycosylation changes | Yes (CDG-II) | Yes (recapitulated) |
| Aberrant cortical neuron migration | Yes | Yes (recapitulated) |
| Globozoospermia | Not a described human feature | Present (round-headed, acrosome-defective sperm) |

**Cellular / in-vitro models.** Patient dermal fibroblasts and ATP6V0A2-knockdown HeLa cells are extensively used and reproduce Golgi fragmentation, delayed BFA-induced retrograde transport, tropoelastin retention, elevated TGF-β, and increased apoptosis (Findings F002, F003).

**Phenotype recapitulation and limitations.** The mouse faithfully models the Golgi-pH, glycosylation, and neuronal-migration axis but adds a reproductive phenotype (globozoospermia) not emphasized in humans, and the fidelity of the cutaneous phenotype requires further characterization. Cellular models capture the trafficking/secretion defect but not the whole-organism, age-dependent attenuation observed clinically.

**Resources.** MGI (mouse), plus patient-derived fibroblast lines and HeLa knockdown systems reported in the primary literature.

---

## Mechanistic Model / Interpretation

ARCL2A is best understood as a **single primary lesion (loss of Golgi V-ATPase a2 subunit) producing a fan of downstream consequences through one shared node — elevated Golgi luminal pH.** Two branches dominate the clinical picture:

1. **Secretory/ECM branch → skin.** Elevated pH and impaired trafficking cause tropoelastin to be retained in a fragmented Golgi, reducing extracellular mature elastin and increasing fibroblast apoptosis. This directly yields cutis laxa. Elevated TGF-β signaling further dysregulates ECM homeostasis. Crucially, downstream elastin crosslinking machinery (lysyl oxidase) and microfibril scaffolding (fibrillin-1) are intact, so the defect is specifically a **secretion/deposition problem**, not a crosslinking or scaffold problem.

2. **Glycosylation/neurodevelopmental branch → brain and biochemistry.** The same pH elevation impairs both N- and O-glycosylation (giving the diagnostic transferrin + apoC-III signature) and disrupts cortical neuron migration, explaining developmental delay, intellectual disability, epilepsy, and gyration abnormalities.

**Upstream vs downstream:** Golgi de-acidification is the upstream hub; glycosylation defects, trafficking delay, tropoelastin retention, TGF-β elevation, apoptosis, and neuronal migration failure are parallel downstream effects. The **age-dependent attenuation** of the skin phenotype, contrasted with the earlier-limited window for cortical migration, explains why systemic/neurological features cluster at younger ages while older patients present predominantly with cutaneous findings.

ARCL2A sits within a coherent **V-ATPase/Golgi cutis-laxa family** — *ATP6V0A2* (ARCL2A), *ATP6V1A* (ARCL2D), *ATP6V1E1* (ARCL2C) — that shares Golgi fragmentation, delayed retrograde transport, and glycosylation abnormalities, plus the mitochondrial proline-cycle disorders *PYCR1* (ARCL2B) and *ALDH18A1* (ARCL3/de Barsy). This unifying pathomechanism (Finding F009) is why molecular confirmation is indispensable:

> *"One group of these metabolic cutis laxa conditions is autosomal recessive cutis laxa type 2 caused by defects in v-ATPase components or the mitochondrial proline cycle."* — [PMID: 33320377](https://pubmed.ncbi.nlm.nih.gov/33320377/)

> *"a fragmented Golgi compartment, a delayed Brefeldin A-induced retrograde transport and glycosylation abnormalities were present in fibroblasts"* — [PMID: 33320377](https://pubmed.ncbi.nlm.nih.gov/33320377/)

---

## Evidence Base

| PMID | Title (abbrev.) | Supports |
|---|---|---|
| [18157129](https://pubmed.ncbi.nlm.nih.gov/18157129/) | Impaired glycosylation and cutis laxa from *ATP6V0A2* | F001 (causal gene), F010 (CDG-II combined N-/O-glyc defect) |
| [33369135](https://pubmed.ncbi.nlm.nih.gov/33369135/) | Review of clinical/molecular variability in ARCL2A | F001 (variant spectrum), F004 (age-dependent phenotype), F008 (attenuated form) |
| [22773132](https://pubmed.ncbi.nlm.nih.gov/22773132/) | Further characterization of ATP6V0A2-related ARCL | F002 (trafficking delay, TGF-β) |
| [39680136](https://pubmed.ncbi.nlm.nih.gov/39680136/) | Golgi pH elevation / V0a2 loss / globozoospermia | F002, F007 (mouse model, Golgi pH → glyc + migration) |
| [19321599](https://pubmed.ncbi.nlm.nih.gov/19321599/) | LOF *ATP6V0A2* impairs trafficking, tropoelastin secretion, survival | F003 (tropoelastin block, NMD, apoptosis) |
| [23963297](https://pubmed.ncbi.nlm.nih.gov/23963297/) | Clinical/biochemical features in neurometabolic cutis laxa | F004 (epilepsy), F009 (differential discriminators) |
| [40043299](https://pubmed.ncbi.nlm.nih.gov/40043299/) | Ocular manifestations in congenital cutis laxa | F005 (corneal/visual acuity, ATP6V0A2-specific) |
| [36728588](https://pubmed.ncbi.nlm.nih.gov/36728588/) | Novel retinal findings in ARCL2A | F005 (macular/chorioretinal scarring) |
| [41732832](https://pubmed.ncbi.nlm.nih.gov/41732832/) | Recurrent exon 16 deletion, founder effect, Türkiye | F006 (founder effect, structural variant) |
| [37119015](https://pubmed.ncbi.nlm.nih.gov/37119015/) | Novel *ATP6V0A2*/*ALDH18A1* variants, Pakistani families | F006 (OMIM ID, AR, consanguinity) |
| [33320377](https://pubmed.ncbi.nlm.nih.gov/33320377/) | Expanding *ATP6V1A* metabolic cutis laxa | F009 (V-ATPase family, shared Golgi pathomechanism) |
| [17170056](https://pubmed.ncbi.nlm.nih.gov/17170056/) | Transferrin + apoC-III IEF complementarity | F010 (biochemical screen) |
| [16037491](https://pubmed.ncbi.nlm.nih.gov/16037491/) | CDG-II subdivided into six biochemical groups | F010 (IEF resolving power) |
| [26538727](https://pubmed.ncbi.nlm.nih.gov/26538727/) | Diagnostic dilemma of cutis laxa | F011 (molecular confirmation required) |
| [26516448](https://pubmed.ncbi.nlm.nih.gov/26516448/) | Congenital cutis laxa type 2 case report | F011 (ARCL2 spectrum constellation) |
| [26320891](https://pubmed.ncbi.nlm.nih.gov/26320891/) | Recurrent Arg138 *ALDH18A1* progeroid cutis laxa | F011 (genetic heterogeneity of overlapping phenotypes) |

**Evidence source types:** human clinical (cohorts, case reports, systematic review), in vitro (patient fibroblasts, HeLa knockdown, pulse-chase, TUNEL), and model organism (*Atp6v0a2* KO mouse). The strongest, most convergent evidence supports the causal gene, the Golgi-pH/glycosylation mechanism, the tropoelastin-secretion basis of cutis laxa, and the diagnostic strategy.

---

## Limitations and Knowledge Gaps

1. **No investigation-specific dataset was analyzed.** This report synthesizes published literature; no primary omics data (transcriptomics, proteomics, metabolomics) were generated or re-analyzed for this job. Detailed molecular-profiling sections (single-cell, spatial, multi-omics, CRISPR screens) are largely unpopulated because such studies for ARCL2A are scarce.
2. **Epidemiology is imprecise.** Formal prevalence/incidence and carrier-frequency estimates are unavailable; the disease is known chiefly through small cohorts and case reports.
3. **Genotype–phenotype correlation is limited.** No specific correlation beyond the null-vs-residual-function distinction has been established; phenotypic variability is incompletely explained.
4. **Quality-of-life and natural-history data are sparse.** No standardized QOL instruments have been applied; long-term outcome data rely on cross-sectional ascertainment.
5. **Modifier genes and epigenetics are unexplored.** No modifier loci or epigenetic mechanisms have been defined.
6. **Model fidelity for skin is uncertain.** The *Atp6v0a2* KO mouse robustly models glycosylation and neuronal migration but the cutaneous phenotype and its age-dependent attenuation require deeper characterization.

---

## Proposed Follow-up Experiments / Actions

1. **Natural-history and registry study** to quantify prevalence, age-dependent progression/attenuation, and standardized QOL (e.g., PROMIS, pediatric instruments) across the ARCL2A spectrum.
2. **Genotype–phenotype meta-analysis** integrating all reported *ATP6V0A2* variants (null vs. residual-function missense/splice) with quantitative phenotype scoring to test whether residual protein function predicts severity.
3. **Single-cell and spatial transcriptomics of patient skin and iPSC-derived cortical organoids** to map cell-type-specific consequences of Golgi de-acidification on tropoelastin secretion and neuronal migration.
4. **Targeted glycomics** (mass-spectrometry N-/O-glycan profiling) to refine the diagnostic biochemical signature beyond IEF and evaluate it as a quantitative biomarker.
5. **Mechanism-based therapeutic screening** using patient fibroblasts and the *Atp6v0a2* KO mouse — e.g., agents that restore Golgi pH homeostasis, enhance tropoelastin secretion, or modulate TGF-β signaling.
6. **Founder-population carrier screening programs** (e.g., southeastern Türkiye) leveraging the recurrent exon 16 deletion for cost-effective cascade testing and reproductive counseling.
7. **Systematic ophthalmologic surveillance protocol** validation, given the ATP6V0A2-specific corneal/retinal burden identified in recent cohorts.

---

*Report compiled from 11 confirmed findings and 30 reviewed papers over a multi-iteration autonomous investigation. Evidence types span human clinical, in vitro, and model-organism studies. Ontology suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) are provided throughout to support knowledge-base ingestion.*


## Artifacts

- [OpenScientist final report](Autosomal_Recessive_Cutis_Laxa_Type_2A-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Autosomal_Recessive_Cutis_Laxa_Type_2A-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 17 |
| Resolved | 17 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 17 |
| On topic | 14 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 41 |
| Resolved | 39 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 1 |
| Unverifiable | 1 |
| Terms whose name was checked | 6 |
| Terms named correctly | 4 |
| Terms named as a **different** term | 1 |
| Terms whose name is worth a second look | 1 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0018163` (2 mentions) - the report calls it "MONDO"; MONDO calls it **autosomal recessive cutis laxa type 2A**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `GO:0006486` (obsolete protein glycosylation) (1 mention) - replaced by `GO:0009101`

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0002269` (1 mention) - the report calls it "Abnormal cortical gyration"; HP calls it **Abnormality of neuronal migration**, and lists "Abnormal neuronal migration" among its other names